Milestone Pharmaceuticals Inc (MIST-Q) Analyst Research & Price Targets - The Globe and Mail

Earnings Estimates

	Current Qtr12/2025	Next Qtr03/2026	Fiscal Yr12/2025	Fiscal Yr12/2026
Average Estimate	-0.18	0.55	-0.71	-0.60
Number of Estimates	3	1	3	3
High Estimate	-0.16	0.55	-0.58	-0.11
Low Estimate	-0.21	0.55	-0.81	-0.98
Prior Year	-0.19	-0.31	-0.67	-0.71
Growth Rate Est. (year over year)	+5.26%	+277.42%	-5.97%	+15.49%

Earnings History - Surprises*

	Qtr Ending09/2025	Qtr Ending06/2025	Qtr Ending03/2025	Qtr Ending12/2024
Reported	$-0.12	$-0.20	$-0.31	$-0.19
Estimate	$-0.17	$-0.18	$-0.19	$-0.15
Difference	+0.05	-0.02	-0.12	-0.04
Surprise	+29.41%	-11.11%	-63.16%	-26.67%

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

4.33

3 Mths Ago6

4.33

2 Mths Ago6

4.67

1 Mth Ago6

4.33

Current6

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	6	6	6	6
	4	4	5	4
Holds	2	2	1	2

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

Insider Report: Chair sells $5-million from this stock yielding 5.8% that’s doubled in under a year

Canaccord reworks U.S. leadership in wake of regulatory settlement

Bullish on FirstEnergy Corp.

The most oversold and overbought stocks on the TSX

Monday’s analyst upgrades and downgrades

Why are Canadian bank valuations so low?

number cruncher

Eleven U.S. semiconductor stocks showing strength

Wednesday’s analyst upgrades and downgrades